Lynk Pharmaceuticals News

Formation Bio Unveils $605M Lynk Deal for CNS-Penetrating TYK2 Inhibitor

December 11, 2025

Formation Bio launches Bleecker Bio subsidiary, securing global rights to Lynk’s CNS-penetrating TYK2 inhibitor in a deal worth up to $605M.